{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T11:14:00Z","timestamp":1768994040314,"version":"3.49.0"},"reference-count":25,"publisher":"BMJ","issue":"9","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2019,8,22]]},"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:p>Antisynthetase syndrome is a rare autoimmune disease and represents a distinct entity within the idiopathic inflammatory myopathies. Its variable systemic manifestations are composed of myositis, interstitial lung disease, non-erosive arthritis, fever, Raynaud\u2019s phenomenon, hyperkeratotic skin changes and the presence of antibodies against aminoacyl-transfer-RNA-synthetases. Interstitial lung disease is the major determinant of morbidity and mortality. The role of lung biopsy remains controversial but it might be considered on an individual basis and may provide information regarding prognosis and treatment response. An integrated clinical, radiological and pathological approach to interstitial lung disease has to be emphasised. Due to the rarity of the disease, no standardised treatment guidelines for antisynthetase syndrome exist. We discuss a patient with anti-Jo1-autoantibody antisynthetase syndrome with proximal myositis and severe, rapid onset, interstitial lung disease with a histopathological pattern of organising pneumonia on surgical lung biopsy and good response to early combined immunosuppressive treatment with corticosteroids, mycophenolate mofetil and rituximab.<\/jats:p>","DOI":"10.1136\/bcr-2019-231006","type":"journal-article","created":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T04:55:15Z","timestamp":1568350515000},"page":"e231006","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":17,"title":["Jo1-antisynthetase syndrome and severe interstitial lung disease with organising pneumonia on histopathology with favourable outcome on early combined treatment with corticosteroids, mycophenolate mofetil and rituximab"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3130-9962","authenticated-orcid":false,"given":"Christine A","family":"R\u00fcegg","sequence":"first","affiliation":[{"name":"Division of Pulmonology, University Hospital Zurich, Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Britta","family":"Maurer","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ir\u00e8ne","family":"Laube","sequence":"additional","affiliation":[{"name":"Division of Pulmonology, Stadtspital Triemli, Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0202-5669","authenticated-orcid":false,"given":"Dieter","family":"Scholtze","sequence":"additional","affiliation":[{"name":"Division of Pulmonology, Stadtspital Triemli, Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,9,12]]},"reference":[{"key":"2025082708512910000_12.9.e231006.1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.10-0180"},{"key":"2025082708512910000_12.9.e231006.2","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12451"},{"key":"2025082708512910000_12.9.e231006.3","doi-asserted-by":"publisher","DOI":"10.1097\/CPM.0000000000000171"},{"key":"2025082708512910000_12.9.e231006.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.03.004"},{"key":"2025082708512910000_12.9.e231006.5","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.161480"},{"key":"2025082708512910000_12.9.e231006.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197502132920706"},{"key":"2025082708512910000_12.9.e231006.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197502202920807"},{"key":"2025082708512910000_12.9.e231006.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14368-1"},{"key":"2025082708512910000_12.9.e231006.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2010.05.008"},{"key":"2025082708512910000_12.9.e231006.10","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-009-0884-9"},{"key":"2025082708512910000_12.9.e231006.11","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21895"},{"key":"2025082708512910000_12.9.e231006.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2014.11.026"},{"key":"2025082708512910000_12.9.e231006.13","first-page":"260","article-title":"High-resolution computed tomography characterization of interstitial lung diseases in polymyositis\/dermatomyositis","volume":"35","author":"Hayashi","year":"2008","journal-title":"J Rheumatol"},{"key":"2025082708512910000_12.9.e231006.14","doi-asserted-by":"publisher","DOI":"10.1055\/s-0034-1371528"},{"key":"2025082708512910000_12.9.e231006.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2014.01.018"},{"key":"2025082708512910000_12.9.e231006.16","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-011-0176-8"},{"key":"2025082708512910000_12.9.e231006.17","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew146"},{"key":"2025082708512910000_12.9.e231006.18","doi-asserted-by":"publisher","DOI":"10.1002\/art.37754"},{"key":"2025082708512910000_12.9.e231006.19","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/art.38270","article-title":"Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis","volume":"66","author":"Aggarwal","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2025082708512910000_12.9.e231006.20","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-013-8408-9"},{"key":"2025082708512910000_12.9.e231006.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2012.01.001"},{"key":"2025082708512910000_12.9.e231006.22","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker305"},{"key":"2025082708512910000_12.9.e231006.23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0133702","article-title":"Efficacy of rituximab in refractory inflammatory myopathies associated with anti- synthetase auto-antibodies: an open-label, phase II trial","volume":"10","author":"Allenbach","year":"2015","journal-title":"PLoS One"},{"key":"2025082708512910000_12.9.e231006.24","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev004"},{"key":"2025082708512910000_12.9.e231006.25","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150844"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2019-231006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T15:51:36Z","timestamp":1756309896000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2019-231006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":25,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,9,12]]},"published-print":{"date-parts":[[2019,9]]}},"alternative-id":["10.1136\/bcr-2019-231006"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2019-231006","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9]]}}}